Catégorie : Cannabis et Réduction des Risques

Associations Between Marijuana Use and Cardiovascular Risk Factors and Outcomes : A Systematic Review, Divya Ravi et al., 2018

Associations Between Marijuana Use and Cardiovascular Risk Factors and Outcomes : A Systematic Review Divya Ravi, MD, MPH; Mehrnaz Ghasemiesfe, MD; Deborah Korenstein, MD; Thomas Cascino, MD; and Salomeh Keyhani, MD, MPH Annals of Internal Medicine, 2018, 168, (3), 187-194. doi : 10.7326/M17-1548      Annals.org Abstract Background : Marijuana use is increasing in the United States, and its effect on cardiovascular health is unknown. Purpose : To review harms and benefits of marijuana use in relation to cardiovascular risk factors and clinical outcomes. Data Sources : PubMed, MEDLINE, EMBASE, PsycINFO, and the Cochrane Library between 1 January 1975 and 30 September 2017. Study Selection : Observational studies that were published [...]

Lire la suite

Bibliographie : Cannabis et Troubles cardio-vasculaires

Bibliographie Cannabis et Troubles cardio-vasculaires   Dr Christian SUEUR, GRECC, 2e édition, janvier 2020.   Actuellement, les méta-analyses ne montrent pas d'augmentation significative des pathologies cardiovasculaire chez les consommateurs de cannabis. (cf en particulier la méta-analyse de Divya RAVI et coll., Annals of Internal Medicine, 2018). Quoiqu'il en soit, l'existence de facteurs de risques liés à la consommation de cannabis fumé est semble-t-il incontestable; de même, les risques sont vraisemblablement augmentés chez les sujets prédisposés, présentant des pathologies cariaques, vasculaires, des troubles de l'excitabilité cardiaque ou de la tension artérielle. La plupart des "Case Report" consistent en des accidents par sténose vasculaire, cérébrale ou cardiaque, [...]

Lire la suite

Characterising heterogeneity in the use of different cannabis products : latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence, Sam Craft et al., 2019

Characterising heterogeneity in the use of different cannabis products : latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence Sam Craft, Adam Winstock, Jason Ferris, Clare Mackie, Michael T. Lynskey and Tom P. Freeman Psychological Medicine, 2019, 1–10. doi : 10.1017/S0033291719002460   Abstract Background. As new cannabis products and administration methods proliferate, patterns of use are becoming increasingly heterogeneous. However, few studies have explored different profiles of cannabis use and their association with problematic use. Methods. Latent class analysis (LCA) was used to identify subgroups of past-year cannabis users endorsing distinct patterns of use from a large international sample [...]

Lire la suite

Stroke in young cannabis users (18-49 years) : National trends in hospitalizations and outcomes, Rupak Desai et al., 2019

Stroke in young cannabis users (18-49 years) : National trends in hospitalizations and outcomes Rupak Desai, Sandeep Singh, Krupa Patel, Hemant Goyal, Manan Shah, Zeeshan Mansuri, Smit Patel, Zabeen K Mahuwala, Larry B Goldstein and Adnan I Qureshi International Journal of Stroke, 2019, doi: 10.1177/1747493019895651 Abstract BACKGROUND : Recent legalization of therapeutic and recreational cannabis use makes it imperative to have an insight into odds and trends in young-onset stroke-related hospitalizations among cannabis users (18-49 years). METHODS : The National Inpatient Sample dataset (2007-2014) was utilized to assess national trends, odds of young-onset stroke-related hospitalizations, and outcomes among cannabis users vs. nonusers using provided discharge weights, [...]

Lire la suite

Beta-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain, Esraa Aly et al.,

Beta-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain Esraa Aly, Maitham A. Khajah and Willias Masocha Molecules, 2020, 25, 106; doi:10.3390/molecules25010106   Abstract : Neuropathic pain associated with nucleoside reverse transcriptase inhibitors (NRTIs), therapeutic agents for human immunodeficiency virus (HIV), responds poorly to available drugs. Smoked cannabis was reported to relieve HIV-associated neuropathic pain in clinical trials. Some constituents of cannabis (Cannabis sativa) activate cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors. However, activation of the CB1 receptor is associated with side eects such as psychosis and physical dependence. Therefore, we investigated the effect of B-caryophyllene (BCP), [...]

Lire la suite

As CBD Oil Flirts with Mainstream, Questions Mount, Kathleen Doheny, Medscape, 2018

As CBD Oil Flirts with Mainstream, Questions Mount Kathleen Doheny Medscape, June 11, 2018 Anxiety is a given for Jessica Singer, 25, who juggles her job at a marijuana dispensary with her night-time gigs as a stand-up comedian in Los Angeles. So when it’s time for bed, "I can't turn off my brain,'' she says. Now she does, with the help of a new bedtime ritual -- a ''snack" of two gummy bears containing CBD. CBD, or cannabidiol, is a substance from marijuana that lacks the ''high'' of the THC (tetrahydro-cannabinol) also found in marijuana. The remedy is affordable for her -- about $35 [...]

Lire la suite

‘Standard THC units’: a proposal to standardize dose across all cannabis products and methods of administration, T.P. Freeman & V.Lorenzetti, 2019

'Standard THC units': a proposal to standardize dose across all cannabis products and methods of administration T.P. Freeman, V.Lorenzetti Addictions, 2019, Oct 12. doi : 10.1111/add.14842 © 2019 Society for the Study of Addiction. Abstract BACKGROUND AND AIMS : Cannabis products are becoming increasingly diverse, and vary considerably in concentrations of ∆9 -tetrahydrocannabinol (THC) and cannabidiol (CBD). Higher doses of THC can increase the risk of harm from cannabis, while CBD may partially offset some of these effects. Lower Risk Cannabis Use Guidelines currently lack recommendations based on quantity of use, and could be improved by implementing standard units. However, there is currently no consensus on [...]

Lire la suite

Driving Under the Influence of Marijuana and Illicit Drugs Among Persons Aged ≥16 Years — United States, 2018, Alejandro Azofeifa et al., 2019,

Driving Under the Influence of Marijuana and Illicit Drugs Among Persons Aged ≥16 Years — United States, 2018 Alejandro Azofeifa, DDS; Bárbara D. Rexach-Guzmán, MPH; Abby N. Hagemeyer, PhD; Rose A. Rudd, MSPH; Erin K. Sauber-Schatz, PhD Morbidity and Mortality Weekly Report, 2019, 68, (50), 1153-1157. https://www.medscape.com/viewarticle/923059?nlid=133476_425&src=WNL_mdplsfeat_200114_mscpedit_psyc&uac=292598PZ&spon=12&impID=2244648&faf=1   Abstract and Introduction Introduction In the United States, driving while impaired is illegal. Nonetheless, an estimated 10,511 alcohol-impaired driving deaths occurred in 2018.* The contribution of marijuana and other illicit drugs to these and other impaired driving deaths remains unknown. Data from the Substance Abuse and Mental Health Services Administration's National Survey on Drug Use and Health (NSDUH) indicated [...]

Lire la suite

Regular Cannabis Use Linked to Cardiac Abnormalities, Fran Lowry, Medscape, 2019.

Regular Cannabis Use Linked to Cardiac Abnormalities Fran Lowry Medscape - Dec 30, 2019. https://www.medscape.com/viewarticle/923220?nlid=133282_2052&src=WNL_mdplsnews_200103_mscpedit_psyc&uac=292598PZ&spon=12&impID=2232271&faf=1 Regular recreational use of cannabis is associated with potentially adverse features of left ventricular size and subclinical impairment of left ventricular function, compared with rare or no cannabis use, an observational study concludes. Previous use of recreational cannabis was not associated with such features, suggesting that any deleterious effects may not be permanent. "These are early data which included a relatively small group of regular cannabis users, and the changes we detected were subtle," lead author Mohammed Y. Khanji, MBBCh, PhD, William Harvey Research Institute, NIHR Barts Biomedical Center, Queen Mary University of London, and [...]

Lire la suite

Cannabis : saurez-vous bien faire la distinction entre le «bien-être» et la «récréation» ?, Jean-Yves NAU, Blog Le Monde, 23 décembre 2019

Cannabis : saurez-vous bien faire la distinction entre le «bien-être» et la «récréation» ? Jean-Yves NAU Blog Le Monde, 23 décembre 2019 Bonjour Est-ce une nouvelle tentative pour dépénaliser/légaliser une substance illicite mais très largement consommée ? L’Assemblée nationale vient de créér une « Mission d’information commune sur la réglementation et l’impact des différents usages du cannabis ». Une mission composée de trente-trois députés et issue des réflexions de … six commissions (affaires économiques, affaires sociales, lois, finances, affaires culturelles et éducatives, développement durable). Pourquoi développer une telle énergie législative ? Parce qu’ « en France  la réglementation des usages du cannabis a particulièrement évolué ces dix dernières années » [il s’agit de [...]

Lire la suite